Loading...
Loading...
PYXS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.7M |
| Gross Profit | -0.7M |
| Operating Expense | 18.1M |
| Operating I/L | -18.1M |
| Other Income/Expense | 2.2M |
| Interest Income | 1.7M |
| Pretax | -15.9M |
| Income Tax Expense | -1.7M |
| Net Income/Loss | -15.9M |
Pyxis Oncology, Inc. is a preclinical stage biopharmaceutical company specializing in the development of immune-oncology therapies. Their product candidates include PYX-106, a siglec-15 targeting antibody for thyroid cancer, head and neck squamous cell carcinoma, NSCLC, and other solid tumors; PYX-102, an immune-therapeutic for solid tumors; and antibody drug conjugate (ADC) product candidates such as PYX-201, PYX-202, and PYX-203 for various cancer treatments.
